Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Factores de riesgo cardiovascular, epidemiología clínica y enfermedad
Resumen
Sin resumen
Texto completo:
PDFReferencias
Gaziano JM. Primary and secondary prevention of coronary heart disease. En: Braunwald E, Zipes DP, Libby P, Bonow R, editors. Braunwald’s heart disease. A textbook of cardio-vascular medicine. Seventh edition. Philadelphia: Saunders; 2005.
Fried VM, Prager K, MacKay AR, Xia H. Chartbook on trends in the health of Americans. Health, United States, 2003. Hyattsville, Maryland: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2003.
Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, et al. Obesity, a worldwide epidemic related to heart disease and stroke. Group III: worldwide comorbidities of obesity. Circulation 2004; 110:476-483.
González-Chávez A, Amancio-Chassin O, Islas-Andrade S, Revilla-Monsalve C, Hernández QM, Lara-Esqueda A, et al. Factores de riesgo cardiovascular asociados a obesidad abdominal en adultos aparentemente sanos. Rev Med Inst Mex Seguro Soc 2008; 46(3):273-279.
Expert Panel on Detection, Evaluation and Treatment of High Blood Colesterol Educational Program (NCEP). Adult Treatment Panel III (ATP III). JAMA 2001; 285:2486-2497.
Reaven GM. Banting lecture 1988. Role of insulin resistance inhuman disease. Diabetes Care 1988; 37:1595-1607.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment insulin resistance and beta —cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
Balkau B, Chrales MA. The European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16:442-443.
Terán-Estrada L, Miranda-Limón JM, Galván-Villegas F. Riesgo cardiovascular derivado de los inhibidores selectivos de la ciclooxigenasa. Rev Med Inst Mex Seguro Soc 2008; 46(3):287-299.
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
Silvernstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroid anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284:1247-1255.
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with arthritis rheumatoid. N Engl J Med 2000; 343:1520-1528.
Bresalier SR, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102.
Cannon CP, Curtis SP, FitzGerald GA. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Programme: a randomized comparison. Lancet 2006; 368:1771-1781.
EDGE Study Group, INCONNU; Baraf HSV, Fuentesalba C, Greenwald M, Brzzicki J, O’Brien K, Soffer B, et al. Gastrointestinal side effects of etericoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. J Rheumatol 2007; 34:408-420.
Solomon DH, Schneeweis S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109:2068-2073.
The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular disease. N Engl J Med 2008; 358:1547-1559.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
Granger CB, McMurray JJ, Yusuf S, Pericak D. Effects of candesartan, enalapril and their combination in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzime-inhibitors: the CHARM alternative trial. Lancet 2003; 362:772-776.
McMurray JJ, Ostergren J, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzime-inhibitors: the CHARM-added trial. Lancet 2003; 362:767-771.
Dahlöf B,Devereux RB, Kjelden SE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003.
Enlaces refback
- No hay ningún enlace refback.